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Background: Geriatric Assessment is an appropriate method for identifying older
cancer patients at risk of life-threatening events during therapy. Yet, it is underused
in practice, mainly because it is time- and resource-consuming. This study aims to
identify the best screening tool to identify older cancer patients requiring geriatric
assessment by comparing the performance of two short assessment tools the G8
and the Vulnerable Elders Survey (VES-13).
Patients and Methods: The diagnostic accuracy of the G8 and the (VES-13) were
evaluated in a prospective cohort study of 1674 cancer patients accrued before
treatment in 23 health care facilities. 1435 were eligible and evaluable. Outcome
measures were multidimensional geriatric assessment (MGA), sensitivity (primary),
specificity, negative and positive predictive values and likelihood ratios of the G8
and VES-13, and predictive factors of 1-year survival rate.
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Results: Patient median age was 78.2 years (70-98) with a majority of females
(69.8%), various types of cancer including 53.9% breast, and 75.8% Performance
Status 0-1. Impaired MGA, G8, and VES-13 were 80.2%, 68.4%, and 60.2%,
respectively. Mean time to complete G8 or VES-13 was about five minutes.
Reproducibility of the two questionnaires was good. G8 appeared more sensitive
(76.5% versus 68.7%, P5 0.0046) whereas VES-13 was more specific (74.3%
versus 64.4%, P,0.0001). Abnormal G8 score (HR52.72), advanced stage
(HR53.30), male sex (HR52.69) and poor Performance Status (HR53.28) were
independent prognostic factors of 1-year survival.
Conclusion: With good sensitivity and independent prognostic value on 1-year
survival, the G8 questionnaire is currently one of the best screening tools available
to identify older cancer patients requiring geriatric assessment, and we believe it
should be implemented broadly in daily practice. Continuous research efforts
should be pursued to refine the selection process of older cancer patients before
potentially life-threatening therapy.
Introduction
Cancer occurs predominantly in the older population, yet patients over 60 years
are significantly under-represented in clinical trials in oncology [1, 2].
Consequently, oncologists are confronted with the paucity of clear therapeutic
directives, and older patients are often offered reduced treatments and face worse
outcomes [3], including an increased risk of toxicity or even early death [4]. With
growing numbers of older cancer patients, and considerable heterogeneity among
them, effective tools are required for oncologists to better define the trade-off
between treatment benefits and toxicity risk.
Several recent reports have strongly suggested that different components of
comprehensive (CGA) or multidimensional geriatric assessment (MGA) can be
useful in oncology to predict early death [4], functional decline [5], toxicity [6, 7]
and ultimately survival [8–10], and to adapt cancer treatment [11]. However,
despite recommendations from the International Society of Geriatric Oncology
(SIOG) [12], CGA is still underused in practice. The likely reason is that it is time-
and resource-consuming, which makes it unaffordable for community and small
cancer hospitals. Furthermore, true CGA (in contrast to MGA which involves the
administration of a range of assessments) is conducted by an experienced
geriatrician who interprets and can act upon the MGA results, and geriatricians
are rarely available in most cancer treatment structures. This has made the
development of shortened instruments essential [13, 14]. To be acceptable for the
whole community, such instruments should be performed quickly (less than
10 min) by a nurse or physician trained for the tool completion, but not
necessarily trained in geriatrics.
The G8 Geriatric Screening Tool
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In response to a French National Cancer Institute (INCa) call for proposal, and
following escalating appeals for validated geriatric screening tools [15–17], we
developed the G8 screening tool to identify older cancer patients requiring
geriatric assessment. The G8 tool originated from a regional multicenter
prospective cohort of 364 cancer patients treated by first-line chemotherapy
[18, 19]. The reference test (or ‘‘gold-standard’’) was defined as at least one
abnormal geriatric assessment test among seven. Preliminary results indicated
85% sensitivity and 65% specificity, which was promising given the priority of a
screening test for maximum sensitivity to minimize the number of patients not
detected.
We subsequently launched the national ONCODAGE multicenter study to
validate the G8 tool prospectively. The primary objective was to validate the G8
instrument as a screening tool to identify older cancer patients (.70 years)
requiring geriatric assessment by comparing with a reference test of MGA.
Secondary objectives included assessing the diagnostic accuracy of G8 in specific
sub-populations, the diagnostic accuracy of VES-13 and comparing it to that of
G8, the within-patient reproducibility of both tests, and the prognostic value of
both tests in terms of 1-year survival. Additional exploratory analyses included the
assessment of the diagnostic accuracy of G8 and VES-13 using a modified
reference test (at least two MGA tests with abnormal scores), and sensitivity




We recruited patients from 23 health care facilities, including the 15 INCa-
accredited Regional Coordination Units for Geriatric Oncology. Patients eligible
were older than 70 years and were included either before any first-line treatment,
or between any two steps of a pre-defined first-line treatment sequence
(chemotherapy, endocrine therapy, targeted treatment, surgery or radiotherapy)
for various types of histologically-confirmed cancer (colon, lung, upper aero
digestive tract (UAT)/head and neck, breast, prostate, and non-Hodgkin’s
lymphomas (NHL)). Patients with known central nervous system metastases were
excluded. Patients were informed of the study and provided their signed informed
consent prior to enrollment and G8/MGA assessment. The protocol was approved
by the regional ethics committee (Comite´ de Protection des Personnes Sud-Ouest
et Outre Mer III), and was conducted in accordance with the Declaration of
Helsinki, Good Clinical Practices (Trial registration: NCT00963911).
The G8 Geriatric Screening Tool
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Test methods
The G8 index test
At the first visit after enrollment, patients received a full clinical examination and
completed the G8 test with a nurse, a clinical research assistant (CRA), or a
physician. The G8 consists of eight items: patient age (.85, 80-85, ,80), and
seven items from the original 18-item MNA (appetite changes, weight loss,
mobility, neuropsychological problems, body mass index, medication, and self-
rated health). The total score ranges from 0 to 17, with lower scores indicating a
higher risk of impairments.[18] The cut-off value for an ‘impaired’ reference test
score was #14 and the time taken to complete the test was recorded. The G8
questionnaire is provided in S1 Appendix.
The VES-13 questionnaire
VES-13 is a self-administered questionnaire that was completed during the first
visit after enrollment. For three pre-identified centers, patients also filled in the
questionnaire at the following geriatric visit. VES-13 consisted of four groups of
questions: age, self-perceived health, difficulties to perform six specific activities,
and difficulties to perform daily living tasks due to health concerns. The score
ranged from 0 to 10 and a score $3 was considered to show impairment.
Multidimensional geriatric assessment (MGA) reference test
Patients underwent a geriatric evaluation in the month following the completion
of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed
six of the seven instruments of the MGA as already described [18] (MNA, Timed
Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL
(IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale
(GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness
Rating Scale (CIRS-G), recorded the time required for the consultation, identified
patients who needed personalized geriatric interventions, and, if necessary,
proposed further geriatric evaluation (outside of the scope of this study). G8
results were blinded to both the geriatrician and the nurse.
Abnormal scores for each instrument were established according to the
following published cut-offs [18]: at least one Grade $3 comorbidity on the
CIRS-G [20] (excluding the cancer being treated); ADL#5, IADL#7 across
genders, MNA#23.5, MMSE#23/30, GDS15$6, and TUG.20 seconds. Based on
preliminary analyses [18], we considered the reference test to be ‘impaired’ if
scores on the seven instruments were available and one or more of them was
abnormal, or if the score on one or more instruments could not be calculated due
to one or more missing item or unavailable instrument.
The reference test was defined as normal if scores for the seven instruments
were available and normal. In a subsequent exploratory analysis, the reference test
was modified and we considered the reference test to be ‘impaired’ if the seven
instruments were available with two or more abnormal scores, or if the score for
two or more instruments could not be calculated due to one or more missing
items or unavailable instruments.
The G8 Geriatric Screening Tool
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Statistical methods
We defined the following populations: the included population, the eligible
population, and the eligible and evaluable population. The included population
corresponded to all patients included, regardless of eligibility and availability of
G8 and MGA results. The eligible population included all patients who did not
violate any eligibility criteria. The eligible and evaluable population for diagnostic
accuracy assessment was defined as all eligible patients, for whom G8 as well as at
least one instrument of MGA were available and were administered less than one
month apart (¡ one week).
Diagnostic accuracy was measured by the classification probabilities (sensitivity
and specificity), positive and negative predictive values (PPV and NPV), and
positive and negative diagnostic likelihood ratios (+/-DLR). The McNemar test
was applied to compare the sensitivity of G8 and VES-13, as well as their
specificity.
The required sample size was estimated based on our preliminary work [18].
Assuming 90% sensitivity for the G8 tool [18], we calculated that the enrollment
of 750 patients with at least one abnormal MGA instrument would allow us to
estimate sensitivity with sufficient precision (2.4%) and to obtain 95%CIs
between 87.6% and 92.4%. Based on an estimated 50% of patients with at least
one abnormal MGA instrument [21], 1500 eligible and evaluable patients were
required. Assuming 10% ineligibility, this involved recruitment of 1650 patients.
The study population was described in terms of clinical and demographic
characteristics with counts and percentages for qualitative variables and summary
statistics (mean and variance where appropriate; percentiles otherwise) for
quantitative variables. Sensitivity, specificity, PPV, NPV, +/-DLR and area under
the ROC curve were estimated with their (two-sided) 95%CI.
Reproducibility analysis was based on estimation of the Kappa agreement
statistics for dichotomous data (normal v abnormal score) [22].
Reproducibility of G8 was assessed by comparing the score on the actual G8
with the scores extracted from the corresponding seven questions of MNA
completed during the MGA for all patients. Reproducibility of VES-13 was
assessed based on a subgroup of patients included in three pre-identified centers
who completed the questionnaire on two occasions. A priori sample size
estimation suggested that enrollment of at least 180 subjects would ensure
sufficient precision to estimate the reproducibility of VES-13 in this subgroup.
The prognostic value of the screening tools was assessed by analyzing one-year
overall survivals using a Cox proportional hazards model. Candidate prognostic
factors included age, sex, ECOG PS (Eastern Cooperative Oncology Group
performance status), stage (metastatic v non-metastatic), and the G8 score.
Significant factors at the univariate stage (p,5%) were subsequently included in a
multivariate model. The final model was based on a manual stepwise backward
selection approach with statistical significance set at 5%. An exploratory model
was also calculated examining the prognostic value of the reference test MGA
score. Hazard ratios (HR) are reported with 95%CIs.
The G8 Geriatric Screening Tool
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Results are presented according to the STARD guidelines [23] for reporting of
studies of diagnostic accuracy, and the study protocol is available in S2 Appendix.
Results
Enrollments
Between August 2008 and March 2010, 1674 patients were included in the
ONCODAGE study. Initial exclusion of 77 ineligible patients left 1597 patients
(eligible population). A further 162 patients were excluded from analyses due to
protocol violations, participation withdrawals, missing G8 or MGA (Fig. 1). Delay
between G8 and MGA exceeded 37 days in 15 cases, and G8 was inadequately
completed by three patients. The final eligible and evaluable population for the
principal analyses consisted of 1435 patients with a median age of 78 years and of
whom 69.5% were females (Table 1). Patients were mostly seen in first
consultations by a medical oncologist (45.6%), surgeons (21.7%), radiotherapists
(13.5%), or other cancer specialists (19.0%).
After the first 779 enrollments, we convened an international independent data
monitoring committee to examine recruitment across different tumor sites and
discuss initial statistical hypotheses. No modification was proposed by the
committee of experts.
The multidimensional geriatric assessment reference standard
results
On average, it took one hour to complete the MGA overall (67.5 minutes, +/-24.6;
range 10 minutes to 3 hours) and it was completed in less than one and a half
hours for 75% of patients. Almost all (91.6%) patients completed the seven
instruments entirely. Rates of completion varied across instruments from 97.0%
for the GDS15 to 99.8% for the ADL and MNA. The proportion of patients with
abnormal scores varied from 15.3% for the ADL to 47.8% for the IADL (Table 2).
Similar results were found for the eligible population (n51597).
Overall, 1151 (80.2%) eligible and evaluable patients were considered to have
an impaired reference test. This was determined for the large majority of patients
(1031, 89.6%) who had an abnormal score on one or more of any of the seven
available instruments. For the remaining 120 patients (10.4%), the score from at
least one instrument was missing and could not be determined. For 85 of these
patients, although at least one score was missing, the score on one of the
remaining instruments was abnormal so their reference test was considered
impaired. For the remaining 35 patients with only five or six available scores, all
available scores were normal. Their reference test was considered to be impaired
for the purposes of the main analyses (see further discussion and analyses in
results).
The G8 Geriatric Screening Tool
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Fig. 1. STARD flow diagram for patient enrollments and exclusions in the ONCODAGE G8 study. Footnote: *In total, ten G8 were incomplete, but six
‘abnormal’ scores were able to be imputed from the incomplete assessments.
doi:10.1371/journal.pone.0115060.g001
The G8 Geriatric Screening Tool
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Of the 1031 patients overall with altered scores, 306 (29.7%) had an altered
score on one instrument, 236 (22.9%) on two, 173 (16.8%) on three, 132 (12.8%)
on four, 94 (9.1%) on five, 73 (7.1%) on six and 17 (1.6%) on seven.
Proportions of subjects with at least one impaired score varied across disease
stage (93.0% for metastatic patients (M1) v 75.1% for non-metastatic (M0)) and
across tumor site (73.0% prostate, 74.2% breast, 86.6% NHL, and 91 to 92% for
colon rectum, lung and UAT/head and neck). At least one geriatric intervention
was proposed by the geriatrician at the end of MGA in 72.2% of the cases and
between one and four per patient in 64.3% of the population. The most frequently
proposed interventions were nutritional support (524 patients, 37.0%), home
assistance (499 patients, 35.2%), standard treatment adaptation (345 patients,
24.3%), psychological support (258 patients, 18.3%) and physiotherapy (231
patients, 16.3%).
Validation of the G8 test
In the eligible and evaluable population (n51435), G8 was mostly administered
by a nurse or CRA (87%) and less frequently by a physician (12.9%). It took an
average of 4.4 minutes to complete (+/22.8, range: 1–60 minutes) with 98.7%
completed in ten minutes or less. The final G8 scores ranged from 1.5 to 17, with
68.4% of patients showing impaired scores (#14). The proportions of patients
with impaired G8 scores varied according to disease stage (85.6% for M1 and
63.0% for M0) and tumor site (36.9% prostate, 62.9% breast, 70.5% NHL, and
85–88% for colon-rectum, lung and UAT/head and neck).
The diagnostic accuracy of G8 is outlined in Table 3. G8 sensitivity was 76.5%
and specificity 64.4%. The AUC compared to the reference standard MGA was
0.804, 95%CI 0.78 to 0.83 (Fig. 2).
G8 was abnormal in 94.4% abnormal MNA (592/627), 93.6% abnormal ADL
(205/219), 91.3% abnormal TGUG (293/321), 84.8% abnormal GDS15 (391/461),
84.5% abnormal IADL (580/686), 80.5% abnormal MMSE (235/292) and 77.4%
abnormal CIRS-G (466/602). Overall, 136 patients with Grade 3-4 comorbidities
had normal G8 scores; this included mainly patients with one severe comorbidity
(58.1%) the most prevalent being vascular (49.3%), cardiac (15.4%), respiratory
(14%) and metabolic (11.8%).
Among false negative results, 53.1% had only one abnormal MGA
questionnaire (median 1; range 1 to 6) as compared to 18.4% in the true positive
group (median 3; range 1 to 7).
Secondary analyses
G8 diagnostic accuracy by subgroups
In terms of disease stage, sensitivity and PPV were superior for M1 patients than
for M0 patients, whereas the specificity and NPV were better for M0 patients
(Sensitivity 5 87.6% (M1) v 71.3% (M0); Specificity 5 43.8% (M1) v 65.7%
(M0); PPV 5 95.8% (M1) v 86.3% (M0); NPV 5 19.4% (M1) v 43.0% (M0))
The G8 Geriatric Screening Tool
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Table 1. Patient and tumor characteristics in the ONCODAGE project.
Eligible Eligible and evaluable
n 5 1597 n 5 1435
Median age (range) (years) 78 (70 to 98) 78 (70 to 98)
70–74 493 (30.9) 444 (30.9)
75–79 481 (30.1) 433 (30.2)
80–84 392 (24.5) 354 (24.7)
85+ 231 (14.5) 204 (14.2)
ECOG PS*
0 608 (38.1) 549 (38.2)
1 518 (32.4) 476 (33.2)
2 225 (14.1) 199 (13.9)
3 93 (5.8) 82 (5.7)
4 48 (3.0) 46 (3.2)
Missing 105 (6.6) 83 (5.8)
Sex
Male 487 (30.5) 434 (30.2)
Tumor site
Breast 852 (53.4) 774(53.9)
Colon-rectum 229 (14.3) 204 (14.2)
Lung 168 (10.5) 149 (10.4)
Prostate 141 (8.8) 122 (8.5)
Non-Hodgkin’s Lymphoma 120 (7.5) 112 (7.8)
Upper Aero Digestive Tract/Head and Neck 87 (5.5) 74 (5.2)
Disease stage**
Non-metastatic (M0) 895 (56.0) 810 (56.4)
Non-metastatic (MX) 269 (16.8) 246 (17.1)
Metastatic (M1) 284 (17.8) 249 (17.3)
Missing 149 (9.3) 130 (9.1)
Treatment performed before evaluation*** 561 (35.1) 497 (34.7)
Surgery 431 (27.0) 384 (26.8)
Endocrine therapy 108 (6.8) 91 (6.3)
Chemotherapy 29 (1.8) 25 (1.7)
Radiotherapy 26 (1.6) 22 (1.5)
Radio-chemotherapy 6 (0.4) 6 (0.4)
Targeted therapy 4 (0.3) 4 (0.3)
Watchful waiting 4 (0.3) 4 (0.3)
Treatment planned after evaluation***
Radiotherapy 662 (41.5) 596 (41.6)
Chemotherapy 559 (35.1) 510 (35.6)
Surgery 518 (32.5) 476 (33.2)
Endocrine therapy 479 (30.1) 433 (30.2)
Targeted therapy 94 (5.9) 83 (5.8)
Radiochemotherapy 72 (4.5) 62 (4.3)
Watchful waiting 23 (1.4) 20 (1.4)
*ECOG PS5eastern cooperative oncology group performance status.
The G8 Geriatric Screening Tool
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(Table 4). Sensitivity and specificity varied significantly according to tumor site:
the sensitivity for prostate cancer patients was 46.1%, 72.3% for breast cancer
patients and 94.1% for UAT/head and neck patients; and specificity ranged from
33.3% for lung cancer patients to 87.9% for prostate cancer patients (Table 4).
A subgroup analysis explored the influence of the presence or absence of at least
one treatment in the last three months. G8 sensitivity or specificity did not appear
to be particularly affected by this factor.
Diagnostic accuracy of VES-13
In the eligible and evaluable population (n51435), VES-13 was mainly
administered with the assistance of a nurse or CRA (78.7%), with 12.1% being
completed by the patient alone, and 8.8% with the assistance of the physician. On
average, it took 5.7 minutes to complete (+/23.2, range1–30 minutes), with 98%
completed in less than 10 minutes.
VES-13 showed impaired scores in 60.2% of patients. Sensitivity and specificity
were 68.7% and 74.3%, respectively (Table 3). The AUC for VES-13 compared to
MGA was 0.79, 95%CI 0.77 to 0.82. Sensitivity and PPV were higher for M1 rather
than for M0 patients (Sensitivity575.1% (M1) v 65.4% (M0); Specificity543.8%
(M1) v 75.6% (M0); PPV595.1% (M1) v 89.0% (M0); NPV510.8% (M1) v
41.9% (M0)).
VES-13 was abnormal in 94.1% abnormal ADL (206/219), 87.5% abnormal
TGUG (281/321), 81.5% abnormal IADL (559/686), 80.9% abnormal GDS15
**Recommendations of the Cancer Care Ontario Practice Guidelines Initiative were implemented.
***As part of the first-line treatment initially planned. More than one treatment possible.
Values are numbers (percentages) unless stated otherwise.
doi:10.1371/journal.pone.0115060.t001
Table 2. Percentages of normal and abnormal scores on the reference standard Multidimensional Geriatric Assessment (MGA) instruments for eligible and
evaluable patients (n51435) and for eligible patients.
Eligible and evaluable (n51435) Eligible (n51597)
Normal Abnormal** Normal Abnormal
MGA instrument* n % n % n % N %
ADL 1216 84.7 219 15.3 1283 84.8 230 15.2
IADL 749 52.2 686 47.8 788 53.3 691 46.7
GDS15 974 67.9 461 32.1 1027 70.2 435 29.8
MMSE 1143 79.6 292 20.3 1203 80.0 300 20.0
MNA 808 56.3 627 43.7 851 56.7 649 43.3
CIRS-G 833 58.0 602 41.9 879 59.4 601 40.6
TGUG 1105 77.0 330 23.0 1162 77.3 341 22.7
*ADL5activities of daily living; IADL5instrumental activities of daily living; GDS5geriatric depression score; MMSE5mini-mental state examination;
MNA5mini nutritional assessment; CIRS-G5comorbidities rating scale – geriatrics; TGUG5 Timed Get Up and Go.
** Abnormal scores were defined per instrument as (for complete instruments): ADL # 5/6, IADL # 7/8, GDS15 $ 6/15, MMSE # 23/30, MNA # 23.5/30,
CIRS-G presence of at least one comorbidity (excluding the cancer being treated), and TGUG. 20 seconds. Incomplete or unavailable instruments were
considered abnormal.
doi:10.1371/journal.pone.0115060.t002
The G8 Geriatric Screening Tool
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(373/461), 77.5% abnormal MNA (486/627), 75.3% abnormal MMSE (220/292)
and 72.4% abnormal CIRS-G (436/602). Overall, VES-13 was normal in 166
patients with Grade 3–4 comorbidities, which included mainly patients with one
severe comorbidity (51.2%), the most prevalent being vascular (45.2%), cardiac
(21.7%), respiratory (14.5%) and psychiatric (12.7%) comorbidities.
Among false negative results, 45.3% had only one abnormal MGA
questionnaire (median 1; range 1 to 6) as compared to 18.1% in the true positive
group (median 3; range 1 to 7).
Comparison of the G8 and VES-13 diagnostic accuracy
The G8 test had a better sensitivity than VES-13 (McNemar test, p5 0.005) at the
expense of a lower specificity (McNemar test, p,0.0001).
G8 and VES-13 reproducibility
Reproducibility for both G8 (n51429) and VES-13 (n5251) was good:
Kappa50.65, (95%CI 0.61 to 0.70), and Kappa50.64, (95%CI 0.54 to 0.73),
respectively. When investigating the items of each instrument, the Kappa
coefficient varied from excellent for objective criteria such as age
(G8: Kappa50.96, 95%CI 0.95 to 0.98; VES-13: Kappa50.98, 95%CI 0.94 to 1.0)
Table 3. Diagnostic accuracy of G8 and Vulnerable Elders Survey (VES-13)* screening tools for identifying older patients who could benefit from
Multidimensional Geriatric Assessment (MGA) for eligible and evaluable population (n51435).
Reference test * Modified reference test *
Estimation (95% CI) 95% CI
G8
Sensitivity 76.5% (73.9 to 78.9) 86.5% (83.9 to 88.7)
Specificity 64.4% (58.6 to 70.0) 55.3% (51.3 to 59.3)
False negative rate 23.5% (21.1 to 26.1) 13.5% (11.2 to 16.1)
False positive rate 35.6% (30.0 to 41.4) 44.7% (40.7 to 48.7)
Positive Predictive Value 89.7% (87.6 to 91.5) 71.7% (68.7 to 74.5)
Negative Predictive Value 40.3% (35.8 to 45.0) 75.8% (71.6 to 79.6)
Positive Likelihood Ratio 2.15 (1.83 to 2.52) 1.93 (1.77 to 2.12)
Negative Likelihood Ratio 0.36 (0.32 to 0.42) 0.24 (0.20 to 0.30)
VES13**
Sensitivity 68.7% (66.0 to 71.4) 78.5% (75.5 to 81.2)
Specificity 74.3% (68.8 to 79.3) 63.7% (59.7 to 67.4)
False negative rate 31.3% (28.6 to 34.0) 21.5% (18.7 to 24.5)
False positive rate 25.7% (20.7 to 31.2) 36.3% (32.5 to 40.2)
Positive Predictive Value 91.6% (89.5 to 93.3) 73.8% (70.8 to 76.7)
Negative Predictive Value 37.0% (33.0 to 41.1) 69.3% (65.4 to 73.1)
Positive Likelihood Ratio 2.67 (2.19 to 3.3) 2.16 (1.93 to 2.41)
Negative Likelihood Ratio 0.42 (0.38 to 0.5) 0.34 (0.29 to 0.39)
*The reference test is defined as one or more abnormal MGA tests; modified reference test is defined as 2 or more abnormal MGA tests.
**Vulnerable Elders survey 13 (French version) [44].
doi:10.1371/journal.pone.0115060.t003
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to poor for subjective criteria such as self-rated health (G8: Kappa50.38; VES-13:
Kappa50.42).
One-year survival of G8 and VES-13
Among the 1435 patients eligible and evaluable, information on vital status was
available for 1365 patients with a median follow-up of 377 days (95%CI 373 to
381). At the univariate level, all candidate prognostic factors were statistically
significant (Table 5). In the final model, factors independently associated with
poorer survival included male sex (HR 2.69, p,0.0001), 2–4 ECOG status (HR
3.28, p,0.0001), metastatic disease (HR 3.30, p,0.0001), and abnormal G8 score
(HR 2.72, p,0.0001) (Table 5).
In a model including all significant candidate prognostic factors and MGA
result, abnormal MGA was found to be significantly associated with poorer
survival at one year (HR 2.96, 95%CI 1.50–5.85, p50.0018).
Fig. 2. ROC curve for G8 test v MGA reference standard in the ONCODAGE study*. Footnote: * For each point on the curve the G8 threshold (above
line) and the sensitivity and specificity (below line) are indicated, e.g. score of 14, sensitivity: 76.4%, specificity: 64.4%. Abbreviations: ROC5 Receiver
Operating Characteristics; MGA5 Multidimensional Geriatric Assessment.
doi:10.1371/journal.pone.0115060.g002
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Table 4. Secondary analyses of diagnostic accuracy of G8 according to subgroups (n51435).
Sensitivity Specificity PPV* NPV*
Non-Metastatic (n) 609 201 503 307
Estimation 71.3 65.7 86.3 43.0
95%CI – lower bound 67.5 58.7 83.0 37.4
95%CI – upper bound 74.8 72.2 89.2 48.7
Metastatic (n) 233 16 213 36
Estimation 87.6 43.8 95.8 19.4
95%CI – lower bound 82.6 19.8 92.1 8.2
95%CI – upper bound 91.5 70.1 98.1 36.0
Stage not available (n) 309 67 265 111
Estimation 78.3 65.7 91.3 39.6
95%CI – lower bound 73.3 53.1 87.3 30.5
95%CI – upper bound 82.8 76.9 94.4 49.4
Breast (n) 574 200 487 287
Estimation 72.3 64.0 85.2 44.6
95%CI – lower bound 68.4 56.9 81.8 38.8
95%CI – upper bound 75.9 70.7 88.3 50.6
Colon-rectum (n) 186 18 174 30
Estimation 87.6 38.9 93.7 23.3
95%CI – lower bound 82.0 17.3 89.0 9.9
95%CI – upper bound 92.0 64.3 96.8 42.3
Lung (n) 137 12 131 18
Estimation 89.8 33.3 93.9 22.2
95%CI – lower bound 83.5 9.9 88.3 6.4
95%CI – upper bound 94.3 65.1 97.3 47.6
Prostate (n) 89 33 45 77
Estimation 46.1 87.9 91.1 37.7
95%CI – lower bound 35.4 71.8 78.8 26.9
95%CI – upper bound 57.0 96.6 97.5 49.4
NHL{ (n) 97 15 79 33
Estimation 76.3 66.7 93.7 30.3
95%CI – lower bound 66.6 38.4 85.8 15.6
95%CI – upper bound 84.3 88.2 97.9 48.7
UAT**/Head and Neck (n) 68 6 65 9
Estimation 94.1 83.3 98.5 55.6
95%CI – lower bound 85.6 35.9 91.7 21.2
95%CI – upper bound 98.4 99.6 100.0 86.3
Previous treatment NO1 (n) 771 166 668 269
Estimation 78.1 60.2 90.1 37.2
95%CI – lower bound 75.0 52.4 87.6 31.4
95%CI – upper bound 80.9 67.7 92.3 43.2
Previous treatment YES1 (n) 380 117 313 184
Estimation 73.2 70.1 88.8 44.6
95%CI – lower bound 68.4 60.9 84.8 37.2
95%CI – upper bound 77.5 78.2 92.1 52.1
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Exploratory analyses
Diagnostic accuracy of G8 and VES-13 with the modified standard
(two abnormal MGA tests)
Using a modified definition of the reference test (two abnormal MGA tests),
56.7% of patients (813 cases) were considered abnormal. G8 sensitivity was 86.5%
and specificity 55.3% (Table 3). The AUC was 0.82, 95%CI 0.80 to 0.84.
Sensitivity and specificity of VES-13 with this modified reference test were 78.5%
and 63.7%, respectively (Table 3).
Sensitivity analysis to assess the impact of missing questionnaires of MGA
For 35 out of 1435 patients, scores for at least five instruments were available and
normal. However, MGA was considered abnormal due to the one or two not fully
completed questionnaires despite normality on all other available instruments. To
specifically account for these patients with missing questionnaires, we investigated
*Positive (PPV) and Negative (NPV) predictive values;
{ Non-Hodgkin’s Lymphoma;
** Upper Aero Digestive Tract;
1Treatment in the last three months.
doi:10.1371/journal.pone.0115060.t004
Table 5. Factors associated with one-year survival (univariate and multivariate models).
Univariate analysis (1365 patients) Multivariate analysis (1167 patients)
Hazard ratio (95% CI*) P value Hazard ratio (95% CI*) P value
Age
70 – 74 Reference 0.0024 Reference 0.5582
75 - 79 1.12 (0.78 to 1.59) 0.85 (0.57 to 1.25)
80 - 84 1.49 (1.04 to 2.12) 0.88 (0.60 to 1.30)
85 and over 1.95 (1.33 to 2.88) 0.72 (0.45 to 1.14)
Sex
Female Reference ,0.0001 Reference ,0.0001
Male 3.09 (2.40 to 3.99) 2.69 (2.02 to 3.58)
ECOG PS*
0-1 Reference ,0.0001 Reference ,0.0001
2-4 5.30 (4.07 to 6.90) 3.28 (2.41 to 4.46)
Stage
Non-metastatic Reference ,0.0001 Reference ,0.0001
Mx** 1.09 (0.69 to 1.69) 1.14 (0.72 to 1.79)
Metastatic 5.67 (4.23 to 7.60) 3.30 (2.42 to 4.50)
G8
Normal Reference ,0.0001 Reference ,0.0001
Abnormal 4.72 (3.07 to 7.26) 2.72 (1.66 to 4.47)
*ECOG PS5 Eastern Cooperative Oncology Group Performance Status.
**Mx 5 Unknown.
doi:10.1371/journal.pone.0115060.t005
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two modified definitions of the reference test. First, if two or less questionnaires
were missing but all other MGA instruments had normal scores, then the
reference test was considered normal, otherwise the definition of our primary
reference test prevailed. Second, the reference test was considered normal as long
as all completed questionnaires had a normal score (regardless of the number of
missing questionnaires).
Using these new definitions of the reference test did not cause changes in the
diagnostic performances of G8 (similar values for sensitivity, specificity, PPV,
NPV and likelihood ratios, data not shown), so the primary definition with these
35 patients considered as abnormal reference tests was maintained.
Discussion
This is the first study designed to determine the diagnostic accuracy of the G8
questionnaire and, by far, the largest prospective cohort available to validate a
screening tool in geriatric oncology with previously published studies including
41–419 patients [24–32]. The G8 test proved to be convenient, easy and quick to
administer. It was generally completed in less than five minutes and was mostly
administered by a nurse with no specific expertise in geriatrics. So far, the G8 tool
exists only in French, but can easily be applied in other languages using the official
English MNA translation (Appendix S1), or one of the 22 other official
translations.
The proportion of G8 impaired scores was 68.4%. In the validation against the
reference test (0 v $1 abnormal MGA tests 2 80% of the population), sensitivity,
of foremost importance for a screening tool, was good at 76.5% and specificity
was satisfactory at 64.4%. With the modified reference test (,2 v $2 abnormal
MGA tests 2 56.7% of the population), sensitivity of G8 was improved to 86.5%
while specificity was reduced to 55.3%.
The population of the study was homogeneously defined including only first-
line cancer treatment patients. As it has been developed in a large number of
investigating centers in France, including community hospitals, and as it can be
equally administered by a nurse or a physician, the G8 questionnaire can be
smoothly implemented in daily practice. However, the large representation of
breast cancer patients included in our study (over 50%) needs to be considered
when generalizing the results. Consequently, we provide diagnostic accuracy
estimations per tumor location in the subgroup analyses. There was a significant
proportion of patients (9.1%) with missing metastatic status for whom physicians
decided not to perform usual pre-treatment work-up because of low risk of
metastasis and age.
Our target population is clearly identified with simple, quantitative criteria: at
least one or two abnormal questionnaires among seven consensus geriatric tools.
However, while MGA appears the best available and most reproducible
instrument to identify it, this target population (reference test) has no unbiased
definition. Two different thresholds considering one [18, 24, 27, 29] or two
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[18, 26, 30–33] abnormal questionnaires have been proposed in the literature with
different sets of questionnaires that more or less cover geriatric domains [34]. So
far, no objective arguments have been raised that enable us to choose the best
threshold [35]. Selecting patients with at least one abnormal questionnaire (80%
of patients in our series, 66% to 94% in other published studies) [18, 24, 27, 29]
reduces the risk of missing unfit patients but also limits the validity of the
screening procedure. With two abnormal tests as the threshold, the target
population is smaller (56.7% in our series vs. 43% to 76% in the literature)
[18, 26, 30–33], which may enable us to concentrate our efforts on the most
vulnerable patients.
While considering sensitivity as the most important criteria (to limit false
negative case occurrences), we believe G8 to be the best available tool, although
VES-13 remains a good alternative with lower sensitivity but higher specificity. In
this study we assessed the performance of VES-13, which is currently the most
widely-used screening tool for older cancer patients, although it was originally
designed to predict functional decline or death over a two-year period in
community-dwelling elders. The higher sensitivity of the G8 screening tool has
been reported in the literature. A previous independent report of 113 patients
found greater sensitivity for G8 (85.7% v 57.1% for VES-13), although the AUC
was not statistically different [33]. A recent systematic review [36] compared all
available screening methods to CGA and reported a median sensitivity for VES-13
of 68% (range 39 to 88%), and median specificity of 78% (range 62 to 100%). The
median sensitivity for G8 was higher at 87% (range 77 to 92%) with a median
specificity of 61% (range 39 to 75%) [36].
VES-13 has been studied as a screening tool in oncology in a number of
previous reports [26, 30, 31, 33, 37] and two of them concluded that VES-13 could
be a useful preliminary screening tool with a sensitivity of 73% and 87% [28, 30].
However, similar analyses reported lower sensitivities ranging from 55 to 68.7%
[26, 31, 33, 37]. These variations may result from differences in administration. In
Luciani et al’s study, VES-13 was administered by a physician and thus possibly
over a longer time and in more detail [38] than in the present study or others,
where VES-13 was administered predominantly by a nurse or CRA.
Additional tools, such as the Barber Questionnaire that was developed as a
screening procedure for older adults in general practice [39] are available but
results reported for older adults with breast cancer are disappointing [31]. Further
geriatric tools have been proposed for screening purposes such as cancer specific
geriatric assessment [40], the abbreviated (a)CGA [41], and the Groningen Frailty
Index (GFI) [42]. However, overall, most of these instruments have only been
presented in feasibility or pilot studies [25], and initial results suggest that they
miss too many cases of vulnerable patients [26].
The false negative rate, undetected unfit patients, was lower with G8 than with
VES-13: 23.5% v 31.3% patients respectively with MGA, and 13.5% v 21.5% with
the modified MGA. The survival analyses demonstrated the strong prognostic role
of the G8 score (HR5 2.72, p,0.0001) along with male sex (HR 2.69, p,0.0001),
poor ECOG status (HR 3.28, p,0.0001) and metastatic disease (HR 3.30,
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p,0.0001). The definition of the reference test was supported by the association
observed between impaired MGA and poorer survival at one year in the
exploratory survival analyses (HR 2.96, p50.0018). With specificity of 64.4% and
NPV of 40.3%, the G8 tool still needs improvement. The somewhat low
reproducibility observed for questions such as neuropsychological problems may
be an issue for improvement, although part of the explanation may be the delay
between the two tests that lasted up to one month.
Considering these results, the G8 questionnaire may be proposed to cancer
patients over 70 years. Given its simplicity, this approach may allow physicians to
discriminate fit from unfit patients. In this way, fit patients can benefit from
standard treatment without extensive evaluation and efforts can be centered on
unfit patients who need careful medical attention. For the latter, if resources are
available, management should be multidisciplinary and based on appropriate
geriatric assessment. If not, they should be offered at least cautious medical
attention and case management when advanced practice nurses can be involved.
In summary, no current consensus exists to define target elderly population
who may benefit from further medical attention before cancer treatment. Our
definition which uses a threshold of one or two abnormal geriatric assessment
questionnaires is probably the most reliable up to now and our exploratory
survival analyses demonstrated the prognostic value of impaired MGA, but search
for a refined reference test remains an issue
This study responds to a critical need for easy and quick-to-use screening tools
to identify older patients requiring more detailed assessment and possible geriatric
interventions. Screening has been recently encouraged for all patients that may
benefit from full CGA in a recent SIOG/EUSOMA publication [43]. First and
foremost, this study documents the high rate of older patients with geriatric
impairments for whom oncologists lack clear directives and skills for practice and
care. The G8 screening method recognizes the heterogeneity of the older patient
population and provides oncologists with a useful, efficient tool to improve care.
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